Heparin natriya (When ATH C05BA03)
When ATH:
C05BA03
Characteristic
Get out of the lungs of cattle. Amorphous white powder with a yellowish tinge, without smell. Soluble in water and saline, pH 1% Water 6-7.5 solution. Active biological method to determine the ability of lengthening the clotting time of blood and expressed in units of.
Pharmacological action
Antykoahulyantnoe.
Application
Unstable angina, acute myocardial infarction; thromboembolic complications of myocardial infarction, operations on the heart and blood vessels, pulmonary and cerebral vessels, thrombophlebitis (Prevention and treatment); DIC, microthrombogenesis prevention and microcirculation disturbances; thrombosis of renal vein; hemolytic uremic syndrome; atrial fibrillation, mitral heart defects (prevention of thrombotic events); bacterial endocarditis; glomerulonephritis; lupus nephritis; rheumatism; bronchial asthma; extracorporeal methods (cardiopulmonary bypass during heart surgery, hemosorption, hemodialysis, pyeritonyealinyi dialysis, tsytaferez), forced diuresis; washing venous catheters.
Contraindications
Gyemorragichyeskii diatyez, leukemia, anemia, increased vascular permeability, Polyps, malignancies and ulcerative lesions GIT, severe liver and kidney, brain surgery and spinal.
Pregnancy and breast-feeding
Category actions result in FDA - C. (The study of reproduction in animals has revealed adverse effects on the fetus, and adequate and well-controlled studies in pregnant women have not held, However, the potential benefits, associated with drugs in pregnant, may justify its use, in spite of the possible risk.)
Side effects
Dizziness, headache, nausea, anorexia, vomiting, diarrhea, alopecia; early (2-4 Days of treatment) and later (Autoimmune) thrombocytopenia; hemorrhagic complications is bleeding in the digestive tract or urinary tract, retroperitoneal bleeding in the ovaries, adrenal (with the development of acute adrenal insufficiency), osteoporosis, calcification of soft tissues, inhibition of the synthesis of aldosterone, elevated transaminase levels in the blood, allergic reactions (fever, rashes, bronchial asthma, anaphylactoid reactions), Local irritation, hematoma, pain when administered.
Cooperation
Efficiency is enhanced with acetylsalicylic acid, dekstranom, Tetracycline, phenylbutazone, ibuprofen, Indomethacin, varfarinom, dikumarinom (the risk of bleeding), weakened-cardiac glycosides, antihistamines, ethacrynic acid, changes — Nicotinic Acid.
Dosing and Administration
P / (deep in the subcutaneous fat, changing injection sites), I / (slowly), / m, inhalation -on 20-50 thousand. U/d, depending on the evidence; w / w loading dose is typically administered 5 th. ED, and then by 20-40 thousand. U/d using infusion pump (use constant or intermittent circuit introduction — on 5-10 thousand. U every 4-6 h); to prevent postoperative thrombosis in/in introducing small doses — 17 th. IU/day for 3-5 days; for the prevention tromboamboliy s/to- 5 th. U 2-8 h before surgery, then every 8 h the same dose administered during the 7 days; to improve microcirculation introducing p/to-an average of 2.5-5th. U 3-4 times a day for 5-7 days, with a gradual decrease in dose.
Precautions
Requires constant monitoring of blood clotting time; cancellation should be done gradually.
Cooperation
Active substance | Description of interaction |
Acrivastine | FMR: antagonizm. Reduces effect. |
Acetylsalicylic acid | FMR: synergism. It increases the risk of hemorrhagic complications. |
Benzathines benzilpenicillin | FMR. Do effect. |
Warfarin | FMR: synergism. Strengthens (mutually) effect, It increases the risk of bleeding. |
Gidroksixloroxin | FMR. It increases the chance of bleeding. |
Gidroxlorotiazid + Captopril | FMR. Against the background of heparin increases the likelihood of developing "kaptoprilovoy" hyperkalemia. |
Dextran | FMR: synergism. It increases the risk of bleeding. |
Digoxin | FMR: antagonizm. Weakens effect. |
Diclofenac | FMR: synergism. It increases the risk of hemorrhagic complications; joint application requires caution. |
Diclofenac potassium | FMR: synergism. It increases the risk of hemorrhagic complications; joint application requires caution. |
Dipiridamol | FMR: synergism. Increases (mutually) effect and the risk of hemorrhagic complications. |
Doxycycline | FMR: antagonizm. Weakens effect. |
Ibuprofen | FMR: synergism. It increases the risk of hemorrhagic complications. |
Indomethacin | FMR: synergism. It increases the risk of hemorrhagic complications. |
Ketoprofen | FMR: synergism. It increases the risk of hemorrhagic complications; joint application requires caution. |
Ketorolac | FMR: synergism. It increases the risk of hemorrhagic complications; joint application requires caution. |
Clopidogrel | FMR: synergism. Increases (mutually) effect and the risk of hemorrhagic complications. |
Loratadine | FMR: antagonizm. Reduces effect. |
Meloxicam | FMR: synergism. It increases the risk of hemorrhagic complications; joint application requires caution. |
Naproxen | FMR: synergism. It increases the risk of hemorrhagic complications; joint application requires caution. |
A nicotinic acid | FMR. Can change effect. |
Piroxicam | FMR: synergism. It increases the risk of hemorrhagic complications; joint application requires caution. |
Promethazine | FMR: antagonizm. Weakens effect. |
Fexofenadine | FMR: antagonizm. Weakens effect. |
Phenylbutazone | FMR: synergism. It increases the risk of hemorrhagic complications. |
Flurbyprofen | FMR: synergism. It increases the risk of hemorrhagic complications; joint application requires caution. |
Cetirizine | FMR: antagonizm. Weakens effect. |
Ciprogeptadin | FMR: antagonizm. Reduces effect. |
Ethacrynic acid | FMR: antagonizm. Reduces effect. |